<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33912905</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: A Set of Patient-Reported Instruments Constructed From Patients' Lived Experience.</ArticleTitle><Pagination><StartPage>278</StartPage><EndPage>287</EndPage><MedlinePgn>278-287</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ciab352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciab352</ELocationID><Abstract><AbstractText Label="BACKGROUND">To develop and validate patient-reported instruments, based on patients' lived experiences, for monitoring the symptoms and impact of long coronavirus disease (covid).</AbstractText><AbstractText Label="METHODS">The long covid Symptom and Impact Tools (ST and IT) were constructed from the answers to a survey with open-ended questions to 492 patients with long COVID. Validation of the tools involved adult patients with suspected or confirmed coronavirus disease 2019 (COVID-19) and symptoms extending over 3 weeks after onset. Construct validity was assessed by examining the relations of the ST and IT scores with health-related quality of life (EQ-5D-5L), function (PCFS, post-COVID functional scale), and perceived health (MYMOP2, Measure yourself medical outcome profile 2). Reliability was determined by a test-retest. The "patient acceptable symptomatic state" (PASS) was determined by the percentile method.</AbstractText><AbstractText Label="RESULTS">Validation involved 1022 participants (55% with confirmed COVID-19, 79% female, and 12.5% hospitalized for COVID-19). The long COVID ST and IT scores were strongly correlated with the EQ-5D-5L (rs&#x2005;=&#x2005;-0.45 and rs&#x2005;=&#x2005;-0.59, respectively), the PCFS (rs&#x2005;=&#x2005;-0.39 and rs&#x2005;=&#x2005;-0.55), and the MYMOP2 (rs&#x2005;=&#x2005;-0.40 and rs&#x2005;=&#x2005;-0.59). Reproducibility was excellent with an interclass correlation coefficient of 0.83 (95% confidence interval .80 to .86) for the ST score and 0.84 (.80 to .87) for the IT score. In total, 793 (77.5%) patients reported an unacceptable symptomatic state, thereby setting the PASS for the long covid IT score at 30 (28 to 33).</AbstractText><AbstractText Label="CONCLUSIONS">The long covid ST and IT tools, constructed from patients' lived experiences, provide the first validated and reliable instruments for monitoring the symptoms and impact of long covid.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Viet-Thi</ForeName><Initials>VT</Initials><Identifier Source="ORCID">0000-0003-1863-6739</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riveros</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clepier</LastName><ForeName>B&#xe9;rang&#xe8;re</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desvarieux</LastName><ForeName>Mo&#xef;se</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collet</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yordanov</LastName><ForeName>Youri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Service d'Accueil des Urgences, H&#xf4;pital Saint Antoine, AP-HP, Sorbonne Universit&#xe9;, Paris,France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, UMR-S, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">patient-reported outcome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33912905</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pii">6252414</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>